Dengue Treatment Market Report 2025

This Dengue Treatment market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The dengue treatment market size has grown rapidly in recent years. It will grow from $2.1 billion in 2024 to $2.35 billion in 2025 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to several factors, including improvements in diagnostic tools, significant efforts by governments and non-governmental organizations (NGOs), the establishment of epidemiological surveillance systems, substantial investments in research and development (R&D), and community education initiatives aimed at raising awareness and preventing dengue.

The dengue treatment market size is expected to see rapid growth in the next few years. It will grow to $3.64 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to the development of universal vaccines, an expansion of vaccine availability, public-private partnerships, the growth of telemedicine, and the enhancement of policy frameworks for better healthcare management. Major trends in the forecast period include the development of next-generation dengue vaccines, the use of artificial intelligence (AI) in drug discovery, the rise of smart contact tracing tools, the exploration of 3D-printed vaccines, and the use of CRISPR technology for targeted virus treatments.

The increasing incidence of dengue is anticipated to drive the growth of the dengue treatment market in the future. Dengue is a mosquito-borne viral infection that causes flu-like symptoms and can lead to severe complications if left untreated. The rise in dengue cases is largely attributed to factors such as urbanization, climate change that favors mosquito breeding, insufficient vector control measures, and population growth in high-risk areas. Timely dengue treatment helps reduce the incidence rate by alleviating severe symptoms, preventing complications, and controlling the spread of the disease through improved patient outcomes and enhanced public health awareness. For example, in 2023, a report by the Centers for Disease Control and Prevention (CDC) highlighted that dengue fever cases in the Americas surged to over 4.6 million, with about 4,000 deaths, marking a 13% increase compared to 2022 and a significant rise from previous years. As a result, the increasing incidence of dengue is expected to fuel market growth in dengue treatment.

Key companies in the dengue treatment market are focusing on innovations such as broad-spectrum antiviral drugs to improve treatment efficacy, reduce disease severity, and address multiple serotypes of the dengue virus simultaneously. Broad-spectrum antiviral drugs are medications effective against a wide range of viruses, rather than targeting a specific one. For example, in September 2024, Hyundai Pharmaceutical Co. Ltd., a South Korea-based pharmaceutical company, launched XAFTY, an innovative broad-spectrum antiviral designed to treat multiple viral infections, including COVID-19 and dengue fever. XAFTY features an advanced drug formulation that improves the absorption and effectiveness of niclosamide, has demonstrated safety and efficacy in clinical trials, targets various RNA viruses, and provides versatility against potential future threats, along with the ability for rapid response in regions facing public health emergencies.

In February 2024, Takeda Pharmaceutical Company, a multinational pharmaceutical company based in Japan, collaborated with Biological E. Limited to enhance the production of its dengue vaccine, TAK-003. This partnership aims to increase the annual production of the vaccine to 50 million doses, ensuring sustainable access in dengue-endemic regions and advancing global efforts in dengue prevention. Biological E. Ltd is an India-based biotechnology company specializing in dengue treatment.

Major players in the dengue treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co Inc., Sanofi S.A., Abbott Laboratories, Novartis International AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cipla Incorporated, Emergent BioSolutions Inc., Bharat Biotech International Limited, Inovio Pharmaceuticals Inc., Gennova Biopharmaceuticals Ltd., ABIVAX S.A., Cadila Healthcare Limited, Biological E. Limited.

Asia-Pacific was the largest region in the dengue treatment in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dengue treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dengue treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Dengue treatment involves the medical management and supportive care for individuals infected with the dengue virus, which is transmitted by Aedes mosquitoes. The treatment primarily focuses on supportive care, such as managing fever with paracetamol, providing hydration through oral or intravenous fluids, and closely monitoring for complications such as bleeding or shock to ensure timely intervention and recovery.

The main types of dengue treatment include vaccines and acetaminophen. Vaccines are biological substances that trigger the body’s immune system to provide immunity against specific diseases. These vaccines can be administered through various routes, including parenteral and oral. The key drug classes involved in dengue treatment include NSAIDs, antibiotics, and corticosteroids, which are distributed through different channels such as hospital pharmacies, retail pharmacies, and online pharmacies. These treatments are used by a range of end users, including hospitals, specialty clinics, and home healthcare settings.

The dengue treatment market research report is one of a series of new reports that provides dengue treatment market statistics, including dengue treatment industry global market size, regional shares, competitors with a dengue treatment market share, detailed dengue treatment market segments, market trends and opportunities, and any further data you may need to thrive in the dengue treatment industry. This dengue treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dengue treatment market consists of sales of products including antipyretics, hydration solutions, blood products, nutritional supplements, diagnostic kits, and protective measures. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.